Life Sciences · NYSE: DHR
Danaher earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 27 Jan 2027
Latest: Q3 2026
Danaher's new CEO is shifting from reshaping the portfolio to connected selling and AI-driven science, launching an autonomous lab and partnering with NVIDIA to turn breadth into a growth edge.
Demand improved across Danaher's end markets. Bioprocessing orders grew mid-teens, led by upstream consumables and resins. Non-respiratory diagnostics grew 7%, helped by Beckman Coulter's strongest quarter in more than two years and Cepheid's non-respiratory tests. The company announced its first AI-powered autonomous lab, a partnership with NVIDIA, and work with Anthropic on instrument connectivity. Leica Biosystems closed its StatLab acquisition, and Masimo kept growing at a high single-digit pace.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $6.5B * |
| Q1 2025 | $5.7B |
| Q2 2025 | $5.9B |
| Q3 2025 | $6.1B |
| Q4 2025 | $6.8B * |
| Q1 2026 | $6.0B |
| Q2 2026 | $6.3B |
| Q3 2026 | $6.6B |
Data
| Q1 2025 | $1.32 |
| Q2 2025 | $0.77 |
| Q3 2025 | $1.27 |
| Q1 2026 | $1.45 |
| Q2 2026 | $1.23 |
| Q3 2026 | $1.75 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 21.8% |
| Q1 2025 | 22.2% |
| Q2 2025 | 12.8% |
| Q3 2025 | 19.1% |
| Q4 2025 | 22.0% |
| Q1 2026 | 22.6% |
| Q2 2026 | 18.0% |
| Q3 2026 | 19.0% |
Data
| Q4 2024 | $1.5B |
| Q1 2025 | $1.1B |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.4B |
| Q4 2025 | $1.7B |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.6B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5Bd | $5.7B | $5.9B | $6.1B | $6.8Bd | $6.0B | $6.3B | $6.6B |
| Gross margin | 59.5% | 61.2% | 59.3% | 58.2% | 58.0% | 60.3% | 57.6% | 58.5% |
| Operating income | $1.4Bd | $1.3B | $760.0M | $1.2B | $1.5Bd | $1.3B | $1.1B | $1.2B |
| Operating margin | 21.8% | 22.2% | 12.8% | 19.1% | 22.0% | 22.6% | 18.0% | 19.0% |
| Net income | $1.1Bd | $954.0M | $555.0M | $908.0M | $1.2Bd | $1.0B | $870.0M | $1.2B |
| Diluted EPS | — | $1.32 | $0.77 | $1.27 | — | $1.45 | $1.23 | $1.75 |
| Operating cash flow | $2.0Bd | $1.3B | $1.3Bd | $1.7Bd | $2.1Bd | $1.3B | $1.5Bd | $1.9Bd |
| Capital expenditure | $516.0Md | $245.0M | $248.0Md | $292.0Md | $371.0Md | $237.0M | $269.0Md | $255.0Md |
| Free cash flow | $1.5B | $1.1B | $1.1B | $1.4B | $1.7B | $1.1B | $1.3B | $1.6B |
| R&D expense | $442.0Md | $379.0M | $403.0M | $378.0M | $438.0Md | $387.0M | $412.0M | $433.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 21 Oct 202610-Q for the period ended 25 Sep 2026SEC ↗
- 21 Jul 202610-Q for the period ended 26 Jun 2026SEC ↗
- 21 Apr 202610-Q for the period ended 27 Mar 2026SEC ↗
- 24 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 21 Oct 202510-Q for the period ended 26 Sep 2025SEC ↗
- 22 Jul 202510-Q for the period ended 27 Jun 2025SEC ↗
- 22 Apr 202510-Q for the period ended 28 Mar 2025SEC ↗
- 20 Feb 202510-K for the period ended 31 Dec 2024SEC ↗